Viatris launches generic for AstraZeneca’s asthma and COPD drug Symbicort

AstraZeneca’s blockbuster asthma and COPD drug Symbicort, which brought in $2.5 billion for the pharma giant in 2022, now has a generics competitor from Viatris.

Viatris teamed up with Kindeva Drug Delivery to launch its own inhalant Breyna, a complex drug-device combo that marks the first outside generic to come to market to compete with Symbicort, Viatris announced Monday. AstraZeneca launched an authorized generic in January 2020.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Men using erectile dysfunction drugs less likely to develop Alzheimer’s disease

Drugs commonly used to treat erectile dysfunction may reduce the risk of Alzheimer’s disease, finds a new study led by UCL researchers.

February 9, 2024

Time-Restricted Eating Tied to Modest Weight Loss

Restricting daily eating to a 10-hour window was no silver bullet for boosting weight loss in people with obesity and prediabetes, a small study found.

April 20, 2024

Researchers call for urgent improvement in pain management for inflammatory arthritis patients

Researchers from Keele University’s School of Medicine have found that analgesic medicines – commonly known as “painkillers” – are widely prescribed to people with inflammatory

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.